ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 189 for:    breast,cancer,prevention | Recruiting, Not yet recruiting, Available Studies

Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02295059
Recruitment Status : Recruiting
First Posted : November 20, 2014
Last Update Posted : November 2, 2016
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Lisa Yee, Ohio State University Comprehensive Cancer Center

Brief Summary:
The investigators study aims to determine biological changes associated with a low vs high dose of omega 3 fatty acids, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), over 12 months in women at risk for recurrent breast cancer. The objectives of the trial are to develop mammary epithelial, adipose tissue specific markers of exposure and response to omega 3 fatty acid supplements that can be carried forward into definitive intervention trials of omega 3 fatty acids for breast cancer prevention. The investigators will randomize 80 subjects with hormone receptor negative, HER-2/neu overexpression positive or negative breast cancer to either a high or low dose of omega 3 fatty acids. Using fine needle aspiration to procure cellular samples of breast epithelial and adipose tissue, the investigators will determine the effects of omega 3 fatty acids on mammary specific biomarkers of response.

Condition or disease Intervention/treatment Phase
Breast Cancer Dietary Supplement: omega 3 fatty acids Phase 1

Detailed Description:
The investigators study aims to determine biological changes that occur with a 12 month intervention of low (~0.9 g EPA+DHA/day) vs high dose (~5.4 g EPA+DHA/day) of omega 3 polyunsaturated fatty acids (PUFAs) in women survivors of hormone unresponsive breast cancer. The objectives of the trial are to develop unique mammary epithelial, adipose tissue specific markers of exposure and response to omega 3 fatty acid supplements that can be carried forward into definitive intervention trials of EPA, DHA/omega 3 PUFAs for breast cancer prevention. The investigators will randomize 80 subjects with hormone receptor negative, HER-2/neu overexpression positive or negative breast cancer to either a high or low dose of omega 3 PUFAs. Using fine needle aspiration to procure cellular samples of breast epithelial and adipose tissue, the investigators will determine the effects of omega 3 fatty acids on mammary specific biomarkers of response.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Omega-3 Fatty Acids and ERPR(-) and HER-2/Neu(+/-) Breast Cancer Prevention
Study Start Date : August 2014
Estimated Primary Completion Date : January 2018
Estimated Study Completion Date : January 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Omega 3 fatty acids - high dose
~5 g EPA+DHA in 5 capsules per day
Dietary Supplement: omega 3 fatty acids
supplied as soft gelatin capsules for oral administration
Other Names:
  • fish oil
  • eicosapentaenoic acid
  • docosahexaenoic acid

Experimental: Omega 3 fatty acids - low dose
~0.9 g EPA+DHA + fatty acids based on the typical American diet in 5 capsules per day
Dietary Supplement: omega 3 fatty acids
supplied as soft gelatin capsules for oral administration
Other Names:
  • fish oil
  • eicosapentaenoic acid
  • docosahexaenoic acid




Primary Outcome Measures :
  1. Changes in eicosanoids/metabolites including PGE2, PGE3 in breast adipose tissue [ Time Frame: Baseline to up to 12 months ]

Secondary Outcome Measures :
  1. Changes in cytomorphology and/or cell proliferation of mammary epithelial cells [ Time Frame: Baseline to up to 12 months ]
  2. Changes in DNA promoter methylation and pro-inflammatory gene expression in mammary epithelial and adipose tissue [ Time Frame: Baseline to up to 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Prior diagnosis of Stage 0 to III breast cancer that is estrogen receptor negative, progesterone receptor negative with completion of definitive surgery, radiation therapy and/or chemotherapy.
  • Completion of chemotherapy or trastuzumab for > six months and of radiation therapy for > 2 months, as applicable and 5 years or less from completion of standard therapy.
  • Greater than 1 year from pregnancy, lactation.
  • Mammogram within the eight months prior to study enrollment that is not suspicious for breast cancer (ACR Class I-III).

Exclusion Criteria:

  • Other current malignancy or metastatic malignancy of any kind.
  • Ongoing chemotherapy, radiation therapy, or other cancer-related treatment.
  • Subjects on Coumadin or other anticoagulants.
  • Subjects with breast implants.
  • Subjects who have had radiation to both breasts or who have undergone bilateral mastectomies.
  • Barriers to fine needle aspiration sampling of breast adipose tissue and/or parenchymal breast tissue, including breast implants, history of radiation to both breasts, bilateral mastectomies, and/or insufficient breast adipose/parenchymal tissue for adequate fine needle aspiration (FNA) sampling.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, hypertension, or psychiatric illness/social situation that would limit compliance with study requirements.
  • Chronic use of omega 3 fatty acid concentrates or capsules within the 3 months prior to entry on the study or any other supplements that might interact with omega 3 fatty acid supplements.
  • Pregnant or nursing women.
  • Known sensitivity or allergy to fish.
  • Subjects on a standing regimen of full dose aspirin (greater than 325 mg/day), NSAIDs (nonsteriodal anti inflammatory drug) or NSAID-containing products.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02295059


Contacts
Contact: Sarah Woelke, BS 614-292-0828 sarah.woelke@osumc.edu

Locations
United States, Ohio
The Ohio State University Comprehensive Cancer Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Sarah Woelke, BS    614-292-0828    sarah.woelke@osumc.edu   
Contact: Lisa D Yee, MD    614-292-0828    lisa.yee@osumc.edu   
Sponsors and Collaborators
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
Investigators
Principal Investigator: Lisa D Yee, MD Ohio State University

Responsible Party: Lisa Yee, Principal Investigator, Ohio State University Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT02295059     History of Changes
Other Study ID Numbers: OSU-13130
1R01CA164019-01A1 ( U.S. NIH Grant/Contract )
First Posted: November 20, 2014    Key Record Dates
Last Update Posted: November 2, 2016
Last Verified: November 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Lisa Yee, Ohio State University Comprehensive Cancer Center:
Breast cancer
ERPR negative
HER-2/neu overexpression positive or negative

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases